BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript

PresentationGreetings, and welcome to the BioXcel Therapeutics KOL Virtual Roundtable Day. It is now my pleasure to introduce Vimal Mehta, CEO. Thank you. You may begin.Vimal MehtaFounder, CEO, President, & Director I'd like to start by welcoming our participants. We are thankful for your leadership and expertise in the Alzheimer's agitation space, particularly as we focus on the significant and underaddressed challenge of acute agitation episodes in Alzheimer's dementia. Next, I would like to thank our mo ...